Eli Lilly Blasted Over Cymbalta Labeling In Side Effect Row
Law360, Washington (August 24, 2015, 9:53 PM EDT) -- Eli Lilly and Co. downplayed the withdrawal risk of its antidepressant drug Cymbalta to the point of fraud, a pair of women told a Virginia federal jury Monday, saying the company portrayed their symptoms as rare when almost half of the patients experienced similar withdrawal.
Brent Wisner, attorney for Gilda Hagan-Brown and Janine Ali, said the two women experienced a raft of new symptoms after they stopped taking Cymbalta in 2012 to treat pain associated with their fibromyalgia, such as depression, migraines, pain, fatigue and sensations of electric shocks — symptoms the label said occurred in “one percent or greater” of...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!